Revvity downgraded to Market Perform from Outperform at Bernstein

Bernstein analyst Eve Burstein downgraded Revvity (RVTY) to Market Perform from Outperform with a $130 price target While the setup in 2025 for U.S. Life Science Tools and Diagnostics “feels a little bit like deja vu,” this time around there is more reason to be optimistic, the analyst tells investors in a research note. There are finally real signs of recovery, with biotech funding up, companies saying that consumable destocking is largely behind us, China stimulus starting to flow, and some first signs that pressure on instruments may be easing, Bernstein says.